SG11202105881RA - Tyrosine kinase inhibitors, compositions and methods there of - Google Patents
Tyrosine kinase inhibitors, compositions and methods there ofInfo
- Publication number
- SG11202105881RA SG11202105881RA SG11202105881RA SG11202105881RA SG11202105881RA SG 11202105881R A SG11202105881R A SG 11202105881RA SG 11202105881R A SG11202105881R A SG 11202105881RA SG 11202105881R A SG11202105881R A SG 11202105881RA SG 11202105881R A SG11202105881R A SG 11202105881RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- tyrosine kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018119895 | 2018-12-07 | ||
| CN2019086204 | 2019-05-09 | ||
| PCT/CN2019/123719 WO2020114499A1 (en) | 2018-12-07 | 2019-12-06 | Tyrosine kinase inhibitors, compositions and methods there of |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105881RA true SG11202105881RA (en) | 2021-07-29 |
Family
ID=70973421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105881RA SG11202105881RA (en) | 2018-12-07 | 2019-12-06 | Tyrosine kinase inhibitors, compositions and methods there of |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210395256A1 (en) |
| EP (1) | EP3891152A4 (en) |
| JP (1) | JP2022510380A (en) |
| KR (1) | KR20210124961A (en) |
| CN (1) | CN113166156B (en) |
| AU (1) | AU2019394520A1 (en) |
| BR (1) | BR112021010930A2 (en) |
| CA (1) | CA3122136A1 (en) |
| IL (1) | IL283599A (en) |
| MX (1) | MX2021006619A (en) |
| PH (1) | PH12021551304A1 (en) |
| SG (1) | SG11202105881RA (en) |
| TW (1) | TW202033526A (en) |
| WO (1) | WO2020114499A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7420403B2 (en) * | 2019-05-08 | 2024-01-23 | ティーワイケー メディシンズ インコーポレーテッド | Compounds used as kinase inhibitors and their applications |
| CN112979654B (en) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业（成都）有限公司 | Heteroaryl fused ring compounds, preparation method and application thereof |
| TW202214635A (en) * | 2020-06-11 | 2022-04-16 | 大陸商貝達藥業股份有限公司 | Salt form, crystal form, pharmaceutical composition and use of tyrosine kinase inhibitor |
| US11524006B2 (en) * | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| CN114315899B (en) * | 2020-09-30 | 2024-09-03 | 上海美迪西生物医药股份有限公司 | 3- (Aromatic ring imidazole) pyrazolopyrimidine derivative and application thereof |
| CN114437075A (en) * | 2020-11-03 | 2022-05-06 | 上海瑶琪生物科技有限公司 | Compounds useful as NTRK kinase inhibitors and their applications |
| US20240317760A1 (en) * | 2021-06-21 | 2024-09-26 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Trk kinase inhibitor compound and use thereof |
| WO2025107298A1 (en) * | 2023-11-24 | 2025-05-30 | 浙江同源康医药股份有限公司 | Crystal, pharmaceutical composition, preparation method therefor, and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI421078B (en) * | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | Checkpoint kinase inhibitors and use thereof |
| AR077468A1 (en) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| PL3233863T3 (en) * | 2014-12-15 | 2024-11-12 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| EP3533796B1 (en) * | 2016-10-28 | 2021-09-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
-
2019
- 2019-12-06 PH PH1/2021/551304A patent/PH12021551304A1/en unknown
- 2019-12-06 EP EP19892359.1A patent/EP3891152A4/en not_active Withdrawn
- 2019-12-06 MX MX2021006619A patent/MX2021006619A/en unknown
- 2019-12-06 SG SG11202105881RA patent/SG11202105881RA/en unknown
- 2019-12-06 JP JP2021531534A patent/JP2022510380A/en active Pending
- 2019-12-06 CA CA3122136A patent/CA3122136A1/en active Pending
- 2019-12-06 BR BR112021010930-7A patent/BR112021010930A2/en not_active Application Discontinuation
- 2019-12-06 AU AU2019394520A patent/AU2019394520A1/en not_active Abandoned
- 2019-12-06 TW TW108144821A patent/TW202033526A/en unknown
- 2019-12-06 KR KR1020217018370A patent/KR20210124961A/en not_active Withdrawn
- 2019-12-06 CN CN201980077490.6A patent/CN113166156B/en active Active
- 2019-12-06 US US17/311,105 patent/US20210395256A1/en not_active Abandoned
- 2019-12-06 WO PCT/CN2019/123719 patent/WO2020114499A1/en not_active Ceased
-
2021
- 2021-06-01 IL IL283599A patent/IL283599A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021010930A2 (en) | 2021-08-24 |
| US20210395256A1 (en) | 2021-12-23 |
| PH12021551304A1 (en) | 2022-05-16 |
| CN113166156A (en) | 2021-07-23 |
| CA3122136A1 (en) | 2021-06-11 |
| MX2021006619A (en) | 2021-07-07 |
| IL283599A (en) | 2021-07-29 |
| EP3891152A1 (en) | 2021-10-13 |
| WO2020114499A1 (en) | 2020-06-11 |
| TW202033526A (en) | 2020-09-16 |
| KR20210124961A (en) | 2021-10-15 |
| EP3891152A4 (en) | 2022-09-07 |
| CN113166156B (en) | 2024-02-27 |
| JP2022510380A (en) | 2022-01-26 |
| AU2019394520A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281805A (en) | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use | |
| IL283599A (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| IL279423A (en) | Polymerases, compositions, and methods of use | |
| ZA202007838B (en) | Polymerases, compositions, and methods of use | |
| IL279258B (en) | Tyrosine kinase inhibitors | |
| PH12018501151A1 (en) | Tank-binding kinase inhibitor compounds | |
| EP3250192A4 (en) | Compositions and methods of using tyrosine kinase inhibitors | |
| SG11202104460UA (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| EP3399968B8 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| EP3648753A4 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| EP3293177A4 (en) | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| IL259862B (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| PL3689351T3 (en) | Quinoline derivative and application thereof as tyrosine kinase inhibitor | |
| EP3328496A4 (en) | Inhibitors of ack1/tnk2 tyrosine kinase | |
| IL264341A (en) | Succinate forms and compositions of bruton's tyrosine kinase inhibitors | |
| SG11202104609SA (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| EP3999064A4 (en) | Inhibitors of tyrosine kinase | |
| SG10201909596RA (en) | Synthesis of Tyrosine Kinase Inhibitors | |
| ZA202103858B (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| EP3699177A4 (en) | Preparation method for tyrosine kinase inhibitor and intermediate thereof |